Tim Church

1 week ago | medcitynews.com | Tim Church |Tomasz Rezik

Dr. Tim Church MD, MPH, PhD, and Chief Medical Officer of Wondr Health is one of the country’s leading clinical thought leaders in exercise and obesity research. As the author of over 300 published clinical articles, Dr. Church has received many awards for his research in preventive health. At Wondr Health, Dr. Church leads the development of program curriculum, which is inspired by his medical expertise.

Jan 8, 2025 | medcitynews.com | Tim Church |Michael Blackman

Dr. Tim Church MD, MPH, PhD, and Chief Medical Officer of Wondr Health is one of the country’s leading clinical thought leaders in exercise and obesity research. As the author of over 300 published clinical articles, Dr. Church has received many awards for his research in preventive health. At Wondr Health, Dr. Church leads the development of program curriculum, which is inspired by his medical expertise.

Oct 9, 2024 | healthcarebusinesstoday.com | Tim Church

Stress impacts more than just our bodies—it significantly influences the health and productivity of organizations. While some stress can actually be beneficial, striking the right balance is a challenge nearly all of us face—we are constantly walking a fine line between embracing healthy stress and being downright stressed out. Recently, Wondr Health conducted a survey with more than 6,000 respondents to learn more about the impact of stress on overall well-being and weight-management.

Sep 25, 2024 | medcitynews.com | Tim Church |Stephanie Baum |Jeff Bak

Dr. Tim Church MD, MPH, PhD, and Chief Medical Officer of Wondr Health is one of the country’s leading clinical thought leaders in exercise and obesity research. As the author of over 300 published clinical articles, Dr. Church has received many awards for his research in preventive health. At Wondr Health, Dr. Church leads the development of program curriculum, which is inspired by his medical expertise.

Aug 21, 2024 | medcitynews.com | Tim Church |Jeff Bak

GLP-1-based agonists (GLP-1s) are transforming the obesity treatment landscape and the positive results keep rolling in. In the last 12 months, there’s been a series of high-profile papers and clinical trials which have demonstrated GLP-1s to prevent or reverse prevalent chronic conditions such as sleep apnea, fatty liver, and CVD. Creating the potential possibility of prescribing these medications beyond the purpose of weight loss and expanding the FDA-approved indications.